The Library

The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya

Tools

Ochola, Rachel, Sande, Charles, Fegan, Gregory, Scott, P. D. (Paul D.), Medley, Graham, Cane, Patricia and Nokes, D. James. (2009) The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One, Vol.4 (No.12). e8088. ISSN 1932-6203

Preview

PDF
WRAP_Medley_Kilifi_Kenya.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (314Kb)

Official URL: http://dx.doi.org/10.1371/journal.pone.0008088

Abstract

Background Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection in infants. The rate of decay of RSV-specific maternal antibodies (RSV-matAb), the factors affecting cord blood levels, and the relationship between these levels and protection from infection are poorly defined. Methods A birth cohort (n = 635) in rural Kenya, was studied intensively to monitor infections and describe age-related serological characteristics. RSV specific IgG antibody (Ab) in serum was measured by the enzyme linked immunosorbent assay (ELISA) in cord blood, consecutive samples taken 3 monthly, and in paired acute and convalescent samples. A linear regression model was used to calculate the rate of RSV-matAb decline. The effect of risk factors on cord blood titres was investigated. Results The half-life of matAb in the Kenyan cohort was calculated to be 79 days (95% confidence limits (CL): 76–81 days). Ninety seven percent of infants were born with RSV-matAb. Infants who subsequently experienced an infection in early life had significantly lower cord titres of anti-RSV Ab in comparison to infants who did not have any incident infection in the first 6 months (P = 0.011). RSV infections were shown to have no effect on the rate of decay of RSV-matAb. Conclusion Maternal-specific RSV Ab decline rapidly following birth. However, we provide evidence of protection against severe disease by RSV-matAb during the first 6–7 months. This suggests that boosting maternal-specific Ab by RSV vaccination may be a useful strategy to consider.

Item Type:	Journal Article
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RJ Pediatrics
Divisions:	Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH):	Respiratory syncytial virus -- Kenya -- Kilifi District, Immunoglobulin G, Maternally acquired immunity -- Kenya -- Kilifi District, Communicable diseases -- Prevention, Enzyme-linked immunosorbent assay, Vaccination
Journal or Publication Title:	PLoS One
Publisher:	Public Library of Science
ISSN:	1932-6203
Date:	2 December 2009
Volume:	Vol.4
Number:	No.12
Page Range:	e8088
Identification Number:	10.1371/journal.pone.0008088
Status:	Peer Reviewed
Access rights to Published version:	Open Access
Funder:	Wellcome Trust (London, England)
Grant number:	061584 (WT), 076278 (WT)
References:	# Loscertales MP, Roca A, Ventura PJ, Abacassamo F, Dos Santos F, et al. (2002) Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique. Pediatr Infect Dis J 21: 148–55. # Roca A, Abacassamo F, Loscertales M-P, Quinto L, Gomez-Olive L X, et al. (2002) Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol 67: 616–23. # Zambon MC, Stockton JD, Clewley JP, Fleming DM (2001) Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 358: 1410–6. # Roca A, Quinto L, Abacassamo F, Loscertales MP, Gomez-Olive FX, et al. (2003) Antibody response after RSV infection in children younger than 1 year of age living in a rural area of Mozambique. J Med Virol 69: 579–87. # Boeck KD (1996) Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Monaldi Arch Chest Dis 51: 210–3. # Brandenburg AH, Groen J, van Steensel-Moll HA, Claas EC, Rothbarth PH, et al. (1997) Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 52: 97–104. # Cox MJ, Azevedo RS, Cane PA, Massad E, Medley GF (1998) Seroepidemiological study of respiratory syncytial virus in Sao Paulo state, Brazil. J Med Virol 55: 234–9. # Lamprecht CL, Krause HE, Mufson MA (1976) Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 134: 211–7. # Hall C, Kopelman A, Douglas RJ, Geiman J, Meagher M (1979) Neonatal respiratory syncytial virus infection. New England Journal of Medicine 300: 393–396. # Neligan GA, Steiner H, Gardner PS, McQuillin J (1970) Respiratory syncytial virus infection of the newborn. Br Med J 3: 146–7. # Nandapalan N, Taylor CE, Greenwell J, Scott M, Scott R, et al. (1986) Seasonal variations in maternal serum and mammary immunity to RS virus. J Med Virol 20: 79–87. # Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL (1981) Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 98: 708–15. # Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140: 543–6. # Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S (1981) Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 7: 263–71. # Ward KA, Lambden PR, Ogilvie M M, Watt PJ (1983) Antibodies to respiratory syncytial virus polypeptides and their significance in human infection. J Gen Virol 64 (Pt 9): 1867–76. # PREVENT (1997) Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 99: 93–9. # IMPACT (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102: 531–7. # Munoz FM, Piedra PA, Glezen WP (2003) Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21: 3465–7. # Englund J, Glezen WP, Piedra PA (1998) Maternal immunization against viral disease. Vaccine 16: 1456–63. # Nokes DJ, Okiro EA, Ngama M, Ochola R, White LJ, et al. (2008) Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya. Clin Infect Dis 46: 50–57. # Nokes DJ, Okiro EA, Ngama M, White LJ, Ochola R, et al. (2004) Respiratory syncytial virus epidemiology in a birth cohort from Kilifi district, Kenya: infection during the first year of life. J Infect Dis 190: 1828–32. # Ministry of Finance and Planning. Analytical report on population projections. Vol VII. Central Bureau of Statistics 2002. Nairobi, Kenya: Central Bureau of Statistics, Government of Kenya. # Wilson SD, Roberts K, Hammond K, Ayres JG, Cane PA (2000) Estimation of incidence of respiratory syncytial virus infection in schoolchildren using salivary antibodies. J Med Virol 61: 81–4. # Sato H, Albrecht P, Reynolds DW, Stagno S, Ennis FA (1979) Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization. Am J Dis Child 133: 1240–3. # Hacimustafaoglu M, Celebi S, Aynaci E, Sinirtas M, Koksal N, et al. (2004) The progression of maternal RSV antibodies in the offspring. Arch Dis Child 89: 52–3. # Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Kobayashi K (2004) Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J Med Virol 72: 304–6. # Caceres VM, Strebel PM, Sutter RW (2000) Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 31: 110–9. # Lee MS, Mendelman PM, Sangli C, Cho I, Mathie SL, et al. (2001) Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants. J Infect Dis 183: 1281–4. # Stensballe LG, Ravn H, Kristensen K, Meakins T, Aaby P, et al. (2009) Seasonal variation of maternally derived Respiratory Syncytial Virus antibodies and association with infant hospitalizations for Respiratory Syncytial Virus. J Pediatr 154: 296–8.
URI:	http://wrap.warwick.ac.uk/id/eprint/2365